ClinicalTrials.gg
CompletedNCT06736223Updated Jun 18, 2026Results posted

Pharmacokinetics, Safety and Tolerability of ITF2357 in Participants With Chronic Hepatic Impairment and With Normal Hepatic Function

A Phase 1 interventional study of ITF2357 in Hepatic Impairment, sponsored by Italfarmaco. Completed at 3 sites in 2 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Italfarmaco · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This was a multicentric, open-label, non-randomized study to evaluate the pharmacokinetic, safety and tolerability of ITF2357 in participants with chronic hepatic impairment relative to matched participants with normal hepatic function.

Read the detailed description

This study evaluated the effect of mild and moderate hepatic impairment (HI) on the pharmacokinetics of ITF2357 and its metabolites, along with the safety and tolerability in this patient population.

The total number of participants enrolled in the study was 24 subjects:

  • 8 participants with mild HI (Child-Pugh class A)
  • 8 participants with moderate HI (Child-Pugh class B)
  • 8 participants with normal hepatic function (control group)

Each participant went through:

  • A screening period from Day (D)-28 to D-2
  • One 6-day/5-night inpatient period (from D-1 evening to D5 morning)
  • An end-of-study evaluation to be done on D10 (±1 day).
02

Conditions studied

  • Hepatic Impairment

Keywords

  • Hepatic impairment
03

In context

Lead sponsor

Italfarmaco is the lead sponsor of 35 studies on the registry; 5 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria for Participants with HI:

  1. Male or female participants, between 18 and 75 years of age, inclusive.
  2. Body weight between 60.0 and 110.0 kg, inclusive if male, and between 50.0 and 100.0 kg, inclusive if female, (BMI) between 18.00 and 34.99 kg/m2, inclusive.
  3. Stable chronic liver disease assessed by medical history, physical examination, laboratory values.
  4. Vital signs after 10 minutes resting in supine position within the following range [or if out of range, considered not (NCS) by the Investigator]: 95 mmHg \< systolic blood pressure (SBP) \< 180 mmHg; 45 mmHg \< diastolic blood pressure (DBP) \< 100 mmHg; 40 bpm \< heart rate (HR) \< 100 bpm.
  5. 12-lead without clinically significant abnormality, in the judgment of the Investigator; in no circumstances were participants enrolled with according to Fridericia (QTcF) > 450 ms.
  6. Any confirmed clinically relevant abnormal laboratory test that, on Investigator's judgment, was inconsistent with the subject's status as a patient with hepatic impairment. However, renal function assessed using the estimated (eGFR) calculated by the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula had to be strictly above 60 mL/min/1.73m².
  7. Female participants who were not pregnant or nursing at screening and D-1, or who were not planning to become pregnant during study period and until 90 days after the IMP administration.
  8. Female participants of non-, defined as one of the following:

    1. At least 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. appropriate age) and follicle-stimulating hormone (FSH) in the range for menopausal female confirmed by blood test according to current local standards at screening;
    2. Those with history of hysterectomy or surgical removal of both ovaries or bilateral tubal ligation performed at least 90 days prior to screening.
  9. Female participant of childbearing potential and male participant (if sexually active with a woman of childbearing potential and not sterile) and his partner had to agree to use an adequate and highly effective method of (according to Clinical Trials Coordination Group [CTCG] recommendations) during the study and for at least 90 days after the study drug administration for women and for men. Such methods include:

    1. combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation oral, intravaginal or transdermal;
    2. progestogen-only hormonal contraception associated with inhibition of ovulation oral, injectable or implantable;
    3. intrauterine device (IUD);
    4. intrauterine hormone-releasing system (IUS);
    5. bilateral tubal occlusion;
    6. vasectomized partner;
    7. sexual abstinence (when in line with the preferred and usual subject's lifestyle).

    Note: Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method (LAM) are not acceptable methods of contraception.

  10. Had given written prior to any procedure related to the study.
  11. Covered by a health insurance system where applicable, and/or in compliance with the recommendations of the national laws in force relating to biomedical research.
  12. Not under any administrative or legal supervision.
  13. For moderate HI cohort: total score ranging from 7 to 9, inclusive.
  14. For mild HI cohort: Child-Pugh total score ranging from 5 to 6, inclusive.
  15. Male participants had to agree not to donate sperm from inclusion up to 3 months after ITF2357 dosing.

Exclusion Criteria for Participants with HI:

  1. Uncontrolled clinically relevant cardiovascular, pulmonary, gastrointestinal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecological (if female), or infectious disease, or signs of acute illness.
  2. Hepatocarcinoma.
  3. Acute hepatitis.
  4. Hepatic encephalopathy grade 2, 3, and 4.
  5. Blood donation within 2 months before inclusion.
  6. Symptomatic postural hypotension, whatever the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease in SBP ≥ 30 mmHg within 3 minutes when changed from supine to standing position.
  7. Presence or history of drug , or allergic disease, except seasonal rhinitis, diagnosed and treated by a physician.
  8. History or presence of regular use of recreational drugs or alcohol abuse (alcohol consumption more than 40 g per day on a regular basis) within 2 years before inclusion.
  9. Smoking more than 15 cigarettes or equivalent per day, unable to refrain from smoking over 5 cigarettes per day from D-1 and throughout the entire institutionalization (i.e. up to D5).
  10. Excessive consumption of beverages with xanthine bases (more than 4 cups or glasses per day).
  11. If female, pregnancy [defined as positive β-human choriogonadotropin (β-HCG) blood test] or breast feeding.
  12. Any significant change in chronic treatment medication within 14 days before inclusion.
  13. Consumption of PgP or BCRP potent inducers or inhibitors that could impact the PK of the product within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic (PD) half-life of the medication before inclusion.

    Note: If any of those drugs was planned to be administered in any of the potential participants, it was postponed for at least until the EOS visit is completed.

  14. Any vaccination, including COVID-19 within 2 weeks before inclusion.
  15. Any participant who, in the judgment of the Investigator, was likely to be noncompliant during the study, or unable to cooperate because of a language problem or poor mental development.
  16. Any participant in the exclusion period of a previous study according to applicable regulations.
  17. Any participant who could not be contacted.
  18. Any participant who was the Investigator or any co-Investigator, research assistant, pharmacist, study coordinator, or other staff thereof, directly involved in conducting the study.
  19. Positive result on any of the following tests: anti- 1 and 2 antibodies (anti-HIV1 and anti-HIV2 Ab).
  20. Positive results on urine drug screen (amphetamines/methamphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates) unless this result was secondary to a documented medical prescription (only for benzodiazepines and cannabinoids).
  21. Positive alcohol breath test.
  22. Any consumption of citrus fruits (grapefruit, Seville orange, etc.) or their juices within 5 days before inclusion.
  23. Medications that prolong the QTc interval (refer to the list provided in Section 12 of Appendix 16.1.1) within 14 days before inclusion or within 7 times the elimination half-life before inclusion.

    Note: If any of those drugs was planned to be administered in any of the potential participants, it was postponed for at least until the last ECG at EOS is completed.

  24. Had a risk factor of QT prolongation (as for example electrolyte imbalances) or a personal or a family history of prolonged QT interval syndrome or torsade de pointes, or family history of sudden death.

Inclusion Criteria for Participants with normal hepatic function:

  1. Male or female participants, between 18 and 75 years of age, inclusive.
  2. Body weight within 10% of the mean body weight of the participants with moderate HI, and BMI between 18.00 and 34.99 kg/m2, inclusive.
  3. Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).
  4. Vital signs after 10 minutes resting in the supine position within the following range (or if out of range, considered NCS by the Investigator): 95 mmHg \< SBP \< 140 mmHg; 45 mmHg \< DBP \< 90 mmHg; 40 bpm \< HR \< 100 bpm.
  5. 12-lead ECG without clinically significant abnormality, in the judgment of the Investigator; in no circumstances participants could have been enrolled with QTcF > 450 ms.
  6. Laboratory parameters within the normal range, unless the Investigator considered an abnormality to be clinically irrelevant for healthy participants, except in the case of , white blood cells and below lower limit of normal (LLN). However serum creatinine, alkaline phosphatase, hepatic enzymes (, alanine aminotransferase), total (unless the participant has documented Gilbert's syndrome, with a maximum bilirubin level lower than 3 x (ULN), and any parameter for which there was an explicit stopping rule could not exceed the upper laboratory range; renal function assessed using the eGFR calculated by the 2021 CKD-EPI formula had to be strictly above 60 mL/min/1.73m².
  7. Female participants who were not pregnant or nursing at screening and D-1, or who were not planning to become pregnant during study period and until 90 days after the IMP administration.
  8. Female participants of non-childbearing potential, defined as one of the following:

    1. At least 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. appropriate age) and FSH in the range for menopausal female confirmed by blood test according to current local standards at screening.
    2. Those with history of hysterectomy or surgical removal of both ovaries or bilateral tubal ligation performed at least 90 days prior to screening.
  9. Female participant of childbearing potential and male participant (if sexually active with a woman of childbearing potential and not sterile) and his partner had to agree to use an adequate and highly effective method of contraception (according to CTCG recommendations) during the study and for at least 90 days after the study drug administration for women and for men. Such methods include:

    1. combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation oral, intravaginal or transdermal;
    2. progestogen-only hormonal contraception associated with inhibition of ovulation oral, injectable or implantable;
    3. intrauterine device (IUD);
    4. intrauterine hormone-releasing system (IUS);
    5. bilateral tubal occlusion;
    6. vasectomized partner;
    7. sexual abstinence (when in line with the preferred and usual subject's lifestyle).

    Note: Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and LAM were not acceptable methods of contraception.

  10. Had given written informed consent prior to any procedure related to the study.
  11. Covered by a health insurance system where applicable, and/or in compliance with the recommendations of the national laws in force relating to biomedical research.
  12. Not under any administrative or legal supervision.
  13. Male participants had to agree not to donate sperm from inclusion up to 3 months after ITF2357 dosing.

Exclusion Criteria for Participants with HI:

  1. Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecological (if female), or infectious disease, or signs of acute illness.
  2. Frequent headaches and/or migraine, recurrent nausea and/or vomiting (more than twice a month).
  3. Blood donation within 2 months before inclusion.
  4. Symptomatic postural hypotension, irrespective of the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease in SBP ≥ 20 mmHg within 3 minutes when changed from supine to standing position.
  5. Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician, except seasonal rhinitis.
  6. History or presence of regular use of recreational drugs or alcohol abuse (alcohol consumption more than 40 g per day on a regular basis) within 2 years before inclusion.
  7. Smoking more than 5 cigarettes or equivalent per day, unable to stop smoking from D-1 and throughout the entire institutionalization (i.e. up to D5).
  8. Excessive consumption of beverages containing xanthine bases (more than 4 cups or glasses per day).
  9. If female, in a status of pregnancy (defined as positive β-HCG blood test), or breast-feeding.
  10. Any medication (including PgP or BCRP inducers or inhibitors, or omeprazole) within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic (PD) half-life of the medication (except HRT and contraception when applicable), any vaccination within the last 28 days (except COVID-19 vaccination) and any biologics (antibody or its derivatives) given within 4 months before inclusion.
  11. Any vaccination, including COVID-19 within 2 weeks before inclusion.
  12. Any participant who, in the judgment of the Investigator, was likely to be noncompliant during the study, or unable to cooperate because of a language problem or poor mental development.
  13. Any participant in the exclusion period of a previous study according to applicable regulations.
  14. Any participant who could not be contacted.
  15. Any participant who was the Investigator or any co-Investigator, research assistant, pharmacist, study coordinator, or other staff thereof, directly involved in conducting the study.
  16. Positive result on any of the following tests: surface antigen (HBs Ag), anti-hepatitis B core antibodies (anti-HBc Ab), anti- virus (anti-HCV) antibodies, anti-HIV1 and anti-HIV2 Ab.
  17. Positive result on urine drug screen (amphetamines/methamphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates).
  18. Positive alcohol breath test.
  19. Any consumption of citrus (grapefruit, Seville orange, etc.) or their juices within 5 days before inclusion.
  20. Had a risk factor of QT prolongation (as for example electrolyte imbalances) or a personal or a family history of prolonged QT interval syndrome or torsade de pointes, or family history of sudden death.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Mild HI

    Patients with mild HI (Child-Pugh class A)

    Drug: ITF2357

  • Experimental
    Moderate HI

    Patients with moderate HI (Child-Pugh class B)

    Drug: ITF2357

  • Experimental
    Healthy Volunteers

    Participants with normal hepatic function (control group)

    Drug: ITF2357

Interventions

  • ITF2357 (INNM Givinostat hydrochloride monohydrate), single dose

    Also known as: Givinostat, Givinostat hydrochloride monohydrate

06

What researchers measure

Primary outcomes

  1. Cmax of ITF2357

    Maximum plasma concentration observed

    Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose

  2. AUClast of ITF2357

    Area under the plasma concentration versus time curve to the real time tlast

    Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose

  3. AUC0-inf of ITF2357

    Area under the plasma concentration versus time curve extrapolated to infinity

    Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose

Secondary outcomes

  1. Tmax of ITF2357

    Time to reach Cmax

    Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose

  2. t1/2 of ITF2357

    Apparent terminal half-life

    Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose

  3. CL/F of ITF2357

    Apparent total plasma clearance from plasma

    Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose

  4. Vz/F of ITF2357

    Apparent volume of distribution

    Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose

  5. Cmax of ITF2357 Metabolites

    Maximum plasma concentration observed

    Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose

  6. AUClast of ITF2357 Metabolites

    Area under the plasma concentration versus time curve to the real time tlast

    Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose

  7. AUC0-inf of ITF2357 Metabolites

    Area under the plasma concentration versus time curve extrapolated to infinity

    Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose

  8. Tmax of ITF2357 Metabolites

    Time to reach Cmax

    Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose

  9. t1/2 of ITF2357 Metabolites

    Apparent terminal half-life

    Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose

  10. Fu of ITF2357 and Its Metabolites

    Unbound fraction (fu) is the fraction of total plasma drug concentration that is not bound to plasma proteins and is pharmacologically available

    Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose

  11. AUC0-last,u of ITF2357 and Its Metabolites

    Unbound area under the plasma concentration versus time curve to the real time Tlast

    Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose

  12. AUC0-inf,u of ITF2357 and Its Metabolites

    Unbound area under the plasma concentration versus time extrapolated to infinity

    Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose

  13. Cmax,u of ITF2357 and Its Metabolites

    Unbound maximum plasma concentration observed

    Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose

  14. CL/Fu of ITF2357

    Unbound apparent total plasma clearance

    Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose

  15. Vz/Fu of ITF2357

    Unbound apparent volume of distribution

    Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose

  16. Incidence of Treatment Emergent Adverse Events (TEAEs)

    Number of participants with at least one related TEAEs. Treatment Emergent Adverse Event is defined as any untoward medical occurrence (including an abnormal laboratory finding, symptom or a disease) in a participant administered the pharmaceutical product and that does not necessarily have to have a causal relationship with this treatment.

    Time frame: From screening (28 to 2 days before administration) to End of Study (9 to 11 days after administration)

  17. Incidence of Treatment-Related TEAEs

    Number of participants with at least one related TEAEs

    Time frame: From screening (28 to 2 days before administration) to End of Study (9 to 11 days after administration)

  18. Severity of Treatment Emergent Adverse Events (TEAEs)

    Number of participants with at least one TEAEs according to NCI-CTCAE grade version 5.0, where severity is classified as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe or medically significant), Grade 4 (life-threatening), and Grade 5 (death related to the adverse event).

    Time frame: From screening (28 to 2 days before administration) to End of Study (9 to 11 days after administration)

  19. Incidence of TEAEs Leading to Withdrawal From the Study

    Number of participants with at least one TEAE leading to withdrawal from the study

    Time frame: From screening (28 to 2 days before administration) to End of Study (9 to 11 days after administration)

  20. Incidence of Serious TEAEs (SAEs)

    Number of participants with at least one Serious TEAE

    Time frame: From screening (28 to 2 days before administration) to End of Study (9 to 11 days after administration)

  21. Incidence of Clinically Significant Clinical Laboratory Parameters Abnormality

    Number of participants with at least one clinically significant laboratory parameters abnormality. The following parameters were measured: Hematology: Hemoglobin, hematocrit, erythrocytes, platelets, leukocytes, and differential counts (basophils, eosinophils, lymphocytes, monocytes, neutrophils). Blood chemistry: Sodium, potassium, chloride, calcium, urea, creatinine, albumin, glucose, total proteins, triglycerides, total cholesterol, ALT, AST, GGT, CPK, alkaline phosphatase, total bilirubin. Coagulation: PT, INR, aPTT. Serology: HBsAg, anti-HBc, anti-HCV, anti-HIV-1/2, pregnancy test (hCG). Urinalysis: pH, protein, glucose, leukocytes, nitrites, ketones, blood. Other: Alcohol breath test; urine drug screen (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates).

    Time frame: From Baseline (28 to 2 days before administration) to End of Study (9 to 11 days after administration)

  22. Incidence of Clinically Significant Vital Signs Abnormality

    Number of participants with at least one clinically significant vitals abnormality. The following clinical signs were measured: body temperature (C°), supine systolic blood pressure (mmHg), diastolic blood pressure (mmHg), pulse rate (beats/min), and respiratory rate (breath/min).

    Time frame: From Baseline (28 to 2 days before administration) to End of Study (9 to 11 days after administration)

  23. Incidence of Clinically Significant Electrocardiogram Abnormality

    Number of participants with at least one clinically significant electrocardiogram abnormality. The following standard 12-lead ECG were recorded: heart rate (beats/min), PR interval (msec), QRS duration (msec), QRS axis (deg), QT interval (msec) and Fridericia and Bazett QTc interval (msec)

    Time frame: From Baseline (28 to 2 days before administration) to End of Study (9 to 11 days after administration)

  24. Incidence of Clinically Significant Physical Examination Abnormality

    Number of participants with at least one clinically significant physical abnormality. A complete physical examination, including at a minimum assessments of the cardiovascular, respiratory, gastrointestinal, dermatological, neurological, and musculoskeletal systems, in addition to examinations of the head, eyes, ears, nose, throat, neck, and lymph nodes, as well as height and weight measurement.

    Time frame: From Baseline (28 to 2 days before administration) to End of Study (9 to 11 days after administration)

07

Results

Posted Jun 18, 2026

Participant flow

A total of 24 participants, 8 participants in each group, were enrolled and completed the study.

Participant flow — Overall Study
MilestoneMild HIModerate HIHealthy Volunteers
Started888
Completed888
Not completed000

Outcome measures

PrimaryCmax of ITF2357

Maximum plasma concentration observed

Time frame:
Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Reported as:
Geometric mean · ng/mL
Cmax of ITF2357
ng/mLMild HIModerate HIHealthy Volunteers
Cmax of ITF235742.54 ± 33.539.19 ± 54.747.21 ± 34.6
Statistical analysis
  • Mild HI vs Moderate HI vs Healthy Volunteers · Regression, Linear · p = 0.8466
  • Mild HI vs Moderate HI vs Healthy Volunteers · Regression, Linear · p = 0.4666
  • Healthy Volunteers · Geometric mean ratio: 47.1028 · 90% CI 35.0437 to 63.3115
  • Mild HI · Geometric mean ratio: 43.0705 · 90% CI 33.9105 to 54.7048
  • Moderate HI · Geometric mean ratio: 40.2878 · 90% CI 30.5450 to 53.1382
  • Mild HI vs Healthy Volunteers · Geometric mean ratio: 0.9144 · 90% CI 0.5787 to 1.4449
  • Moderate HI vs Healthy Volunteers · Geometric mean ratio: 0.8553 · 90% CI 0.4992 to 1.4653
PrimaryAUClast of ITF2357

Area under the plasma concentration versus time curve to the real time tlast

Time frame:
Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Reported as:
Geometric mean · h*ng/mL
AUClast of ITF2357
h*ng/mLMild HIModerate HIHealthy Volunteers
AUClast of ITF2357272.17 ± 38.1207.85 ± 43.3306.20 ± 25.0
Statistical analysis
  • Mild HI vs Moderate HI vs Healthy Volunteers · Regression, Linear · p = 0.1584
  • Mild HI vs Moderate HI vs Healthy Volunteers · Regression, Linear · p = 0.0675
  • Healthy Volunteers · Geometric mean ratio: 301.7783 · 90% CI 246.8445 to 368.9372
  • Mild HI · Geometric mean ratio: 280.2165 · 90% CI 238.1972 to 329.6482
  • Moderate HI · Geometric mean ratio: 219.0518 · 90% CI 181.4912 to 264.3858
  • Mild HI vs Healthy Volunteers · Geometric mean ratio: 0.9286 · 90% CI 0.6805 to 1.2671
  • Moderate HI vs Healthy Volunteers · Geometric mean ratio: 0.7259 · 90% CI 0.5035 to 1.0465
PrimaryAUC0-inf of ITF2357

Area under the plasma concentration versus time curve extrapolated to infinity

Time frame:
Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Reported as:
Geometric mean · h*ng/mL
AUC0-inf of ITF2357
h*ng/mLMild HIModerate HIHealthy Volunteers
AUC0-inf of ITF2357287.92 ± 36.7223.54 ± 41.9319.45 ± 23.7
Statistical analysis
  • Mild HI vs Moderate HI vs Healthy Volunteers · Regression, Linear · p = 0.1793
  • Mild HI vs Moderate HI vs Healthy Volunteers · Regression, Linear · p = 0.0795
  • Healthy Volunteers · Geometric mean ratio: 315.1302 · 90% CI 259.6512 to 382.4632
  • Mild HI · Geometric mean ratio: 295.5819 · 90% CI 252.7434 to 345.6813
  • Moderate HI · Geometric mean ratio: 234.7970 · 90% CI 195.8683 to 281.4629
  • Mild HI vs Healthy Volunteers · Geometric mean ratio: 0.9380 · 90% CI 0.6952 to 1.2656
  • Moderate HI vs Healthy Volunteers · Geometric mean ratio: 0.7451 · 90% CI 0.5237 to 1.0600
SecondaryTmax of ITF2357

Time to reach Cmax

Time frame:
Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Reported as:
Mean · hours
Tmax of ITF2357
hoursMild HIModerate HIHealthy Volunteers
Tmax of ITF23572.000 ± 1.00-4.002.000 ± 0.50-4.001.000 ± 1.000-5.00
Secondaryt1/2 of ITF2357

Apparent terminal half-life

Time frame:
Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Reported as:
Geometric mean · hours
t1/2 of ITF2357
hoursMild HIModerate HIHealthy Volunteers
t1/2 of ITF23577.8876 ± 14.57.7619 ± 22.47.0450 ± 10.6
SecondaryCL/F of ITF2357

Apparent total plasma clearance from plasma

Time frame:
Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Reported as:
Geometric mean · L/h
CL/F of ITF2357
L/hMild HIModerate HIHealthy Volunteers
CL/F of ITF2357173.6618 ± 36.7223.6763 ± 41.9156.5170 ± 23.7
SecondaryVz/F of ITF2357

Apparent volume of distribution

Time frame:
Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Reported as:
Geometric mean · L
Vz/F of ITF2357
LMild HIModerate HIHealthy Volunteers
Vz/F of ITF23571976.1675 ± 31.82504.7280 ± 39.31590.7968 ± 24.0
SecondaryCmax of ITF2357 Metabolites

Maximum plasma concentration observed

Time frame:
Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Reported as:
Geometric mean · ng/mL
Cmax of ITF2357 Metabolites
ng/mLMild HIModerate HIHealthy Volunteers
ITF23746.34 ± 41.46.11 ± 36.57.57 ± 36.9
ITF2375108.28 ± 55.382.31 ± 45.6125.30 ± 28.4
Statistical analysis
  • Mild HI vs Moderate HI vs Healthy Volunteers · Regression, Linear · p = 0.6005
  • Mild HI vs Moderate HI vs Healthy Volunteers · Regression, Linear · p = 0.7669
  • Healthy Volunteers · Geometric mean ratio: 7.7940 · 90% CI 5.7064 to 10.6453
  • Mild HI · Geometric mean ratio: 6.2336 · 90% CI 4.8446 to 8.0206
  • Moderate HI · Geometric mean ratio: 5.9364 · 90% CI 4.4338 to 7.9483
  • Mild HI vs Healthy Volunteers · Geometric mean ratio: 0.7998 · 90% CI 0.4938 to 1.2955
  • Moderate HI vs Healthy Volunteers · Geometric mean ratio: 0.7617 · 90% CI 0.4318 to 1.3435
  • Mild HI vs Moderate HI vs Healthy Volunteers · Regression, Linear · p = 0.2803
  • Mild HI vs Moderate HI vs Healthy Volunteers · Regression, Linear · p = 0.2027
  • Healthy Volunteers · Geometric mean ratio: 128.2984 · 90% CI 94.8209 to 173.5955
  • Mild HI · Geometric mean ratio: 110.9599 · 90% CI 86.8942 to 141.6907
  • Moderate HI · Geometric mean ratio: 84.0221 · 90% CI 63.3086 to 111.5125
  • Mild HI vs Healthy Volunteers · Geometric mean ratio: 0.8649 · 90% CI 0.5417 to 1.3807
  • Moderate HI vs Healthy Volunteers · Geometric mean ratio: 0.6549 · 90% CI 0.3777 to 1.1356
SecondaryAUClast of ITF2357 Metabolites

Area under the plasma concentration versus time curve to the real time tlast

Time frame:
Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Reported as:
Geometric mean · h*ng/mL
AUClast of ITF2357 Metabolites
h*ng/mLMild HIModerate HIHealthy Volunteers
ITF2374138.59 ± 55.3118.87 ± 37.4179.47 ± 75.6
ITF23751160.24 ± 74.6835.66 ± 47.01588.77 ± 91.3
Statistical analysis
  • Mild HI vs Moderate HI vs Healthy Volunteers · Regression, Linear · p = 0.6425
  • Mild HI vs Moderate HI vs Healthy Volunteers · Regression, Linear · p = 0.3687
  • Healthy Volunteers · Geometric mean ratio: 178.8660 · 90% CI 116.8182 to 273.8703
  • Mild HI · Geometric mean ratio: 143.0978 · 90% CI 101.4002 to 201.9421
  • Moderate HI · Geometric mean ratio: 123.5751 · 90% CI 82.9335 to 184.1331
  • Mild HI vs Healthy Volunteers · Geometric mean ratio: 0.8000 · 90% CI 0.4139 to 1.5465
  • Moderate HI vs Healthy Volunteers · Geometric mean ratio: 0.6909 · 90% CI 0.3181 to 1.5004
  • Mild HI vs Moderate HI vs Healthy Volunteers · Regression, Linear · p = 0.4583
  • Mild HI vs Moderate HI vs Healthy Volunteers · Regression, Linear · p = 0.6224
  • Healthy Volunteers · Geometric mean ratio: 1579.5107 · 90% CI 932.0769 to 2676.6612
  • Mild HI · Geometric mean ratio: 1182.6496 · 90% CI 772.0455 to 1811.6291
  • Moderate HI · Geometric mean ratio: 862.9195 · 90% CI 526.6587 to 1413.8758
  • Mild HI vs Healthy Volunteers · Geometric mean ratio: 0.7487 · 90% CI 0.3311 to 1.6932
  • Moderate HI vs Healthy Volunteers · Geometric mean ratio: 0.5463 · 90% CI 0.2091 to 1.4271
SecondaryAUC0-inf of ITF2357 Metabolites

Area under the plasma concentration versus time curve extrapolated to infinity

Time frame:
Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Reported as:
Geometric mean · h*ng/mL
AUC0-inf of ITF2357 Metabolites
h*ng/mLMild HIModerate HIHealthy Volunteers
ITF2374NA ± NA165.95 ± 27.2239.11 ± 59.8
ITF23751195.40 ± 74.5865.47 ± 46.01630.94 ± 89.2
Statistical analysis
  • Mild HI vs Moderate HI vs Healthy Volunteers · Regression, Linear · p = 0.8699
  • Mild HI vs Moderate HI vs Healthy Volunteers · Regression, Linear · p = 0.9654
  • Healthy Volunteers · Geometric mean ratio: 232.2588 · 90% CI 87.8926 to 613.7509
  • Mild HI · Geometric mean ratio: 214.3007 · 90% CI 92.4027 to 497.0066
  • Moderate HI · Geometric mean ratio: 170.4802 · 90% CI 78.0378 to 372.4286
  • Mild HI vs Healthy Volunteers · Geometric mean ratio: 0.9227 · 90% CI 0.1719 to 4.9527
  • Moderate HI vs Healthy Volunteers · Geometric mean ratio: 0.7340 · 90% CI 0.1228 to 4.3888
  • Mild HI vs Moderate HI vs Healthy Volunteers · Regression, Linear · p = 0.4574
  • Mild HI vs Moderate HI vs Healthy Volunteers · Regression, Linear · p = 0.6057
  • Healthy Volunteers · Geometric mean ratio: 1624.0033 · 90% CI 964.6539 to 2734.0237
  • Mild HI · Geometric mean ratio: 1219.3246 · 90% CI 800.2301 to 1857.9062
  • Moderate HI · Geometric mean ratio: 893.1141 · 90% CI 548.4525 to 1454.3698
  • Mild HI vs Healthy Volunteers · Geometric mean ratio: 0.7508 · 90% CI 0.3354 to 1.6807
  • Moderate HI vs Healthy Volunteers · Geometric mean ratio: 0.5499 · 90% CI 0.2131 to 1.4195
SecondaryTmax of ITF2357 Metabolites

Time to reach Cmax

Time frame:
Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Reported as:
Median · hours
Tmax of ITF2357 Metabolites
hoursMild HIModerate HIHealthy Volunteers
ITF23746.000 (4.00 to 10.00)5.000 (4.00 to 10.02)12.000 (3.00 to 24.00)
ITF23752.500 (2.50 to 4.00)3.000 (2.00 to 3.00)2.500 (2.03 to 10.00)
Secondaryt1/2 of ITF2357 Metabolites

Apparent terminal half-life

Time frame:
Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Reported as:
Geometric mean · hours
t1/2 of ITF2357 Metabolites
hoursMild HIModerate HIHealthy Volunteers
ITF2374NA ± NA12.3264 ± 12.014.1083 ± 47.4
ITF237513.6579 ± 35.812.5157 ± 24.313.9453 ± 25.6
SecondaryFu of ITF2357 and Its Metabolites

Unbound fraction (fu) is the fraction of total plasma drug concentration that is not bound to plasma proteins and is pharmacologically available

Time frame:
Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Reported as:
Geometric mean · % of unbound fraction
Fu of ITF2357 and Its Metabolites
% of unbound fractionMild HIModerate HIHealthy Volunteers
ITF23574.5044 ± 22.74.8945 ± 21.83.7642 ± 17.1
ITF23748.0631 ± 14.08.5972 ± 13.67.4527 ± 18.7
ITF23751.1150 ± 11.91.2801 ± 19.21.0433 ± 11.6
SecondaryAUC0-last,u of ITF2357 and Its Metabolites

Unbound area under the plasma concentration versus time curve to the real time Tlast

Time frame:
Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Reported as:
Geometric mean · h*ng/mL
AUC0-last,u of ITF2357 and Its Metabolites
h*ng/mLMild HIModerate HIHealthy Volunteers
ITF235712.26 ± 41.510.17 ± 35.511.53 ± 36.2
ITF237411.18 ± 54.210.47 ± 37.913.38 ± 86.1
ITF237512.94 ± 65.510.70 ± 46.316.58 ± 86.5
SecondaryAUC0-inf,u of ITF2357 and Its Metabolites

Unbound area under the plasma concentration versus time extrapolated to infinity

Time frame:
Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Reported as:
Geometric mean · h*ng/mL
AUC0-inf,u of ITF2357 and Its Metabolites
h*ng/mLMild HIModerate HIHealthy Volunteers
ITF235712.97 ± 40.110.94 ± 34.712.02 ± 34.8
ITF2374NA ± NA12.72 ± 31.817.73 ± 58.8
ITF237513.33 ± 65.411.08 ± 45.417.02 ± 84.6
SecondaryCmax,u of ITF2357 and Its Metabolites

Unbound maximum plasma concentration observed

Time frame:
Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Reported as:
Geometric mean · ng/mL
Cmax,u of ITF2357 and Its Metabolites
ng/mLMild HIModerate HIHealthy Volunteers
ITF23571.92 ± 44.41.92 ± 46.51.78 ± 37.6
ITF23740.51 ± 46.60.52 ± 30.80.56 ± 41.6
ITF23751.21 ± 53.21.05 ± 45.91.31 ± 27.9
SecondaryCL/Fu of ITF2357

Unbound apparent total plasma clearance

Time frame:
Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Reported as:
Geometric mean · L/h
CL/Fu of ITF2357
L/hMild HIModerate HIHealthy Volunteers
CL/Fu of ITF23573855.3955 ± 40.14569.9699 ± 34.74158.0773 ± 34.8
SecondaryVz/Fu of ITF2357

Unbound apparent volume of distribution

Time frame:
Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Reported as:
Geometric mean · L
Vz/Fu of ITF2357
LMild HIModerate HIHealthy Volunteers
Vz/Fu of ITF235743872.1021 ± 37.851174.5320 ± 34.142261.5883 ± 35.8
SecondaryIncidence of Treatment Emergent Adverse Events (TEAEs)

Number of participants with at least one related TEAEs. Treatment Emergent Adverse Event is defined as any untoward medical occurrence (including an abnormal laboratory finding, symptom or a disease) in a participant administered the pharmaceutical product and that does not necessarily have to have a causal relationship with this treatment.

Time frame:
From screening (28 to 2 days before administration) to End of Study (9 to 11 days after administration)
Reported as:
Count of participants · Participants
Incidence of Treatment Emergent Adverse Events (TEAEs)
ParticipantsMild HIModerate HIHealthy Volunteers
Incidence of Treatment Emergent Adverse Events (TEAEs)021
SecondaryIncidence of Treatment-Related TEAEs

Number of participants with at least one related TEAEs

Time frame:
From screening (28 to 2 days before administration) to End of Study (9 to 11 days after administration)
Reported as:
Count of participants · Participants
Incidence of Treatment-Related TEAEs
ParticipantsMild HIModerate HIHealthy Volunteers
Incidence of Treatment-Related TEAEs000
SecondarySeverity of Treatment Emergent Adverse Events (TEAEs)

Number of participants with at least one TEAEs according to NCI-CTCAE grade version 5.0, where severity is classified as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe or medically significant), Grade 4 (life-threatening), and Grade 5 (death related to the adverse event).

Time frame:
From screening (28 to 2 days before administration) to End of Study (9 to 11 days after administration)
Reported as:
Count of participants · Participants
Severity of Treatment Emergent Adverse Events (TEAEs)
ParticipantsMild HIModerate HIHealthy Volunteers
Grade 1020
Grade 2001
Grade ≥ 3000
SecondaryIncidence of TEAEs Leading to Withdrawal From the Study

Number of participants with at least one TEAE leading to withdrawal from the study

Time frame:
From screening (28 to 2 days before administration) to End of Study (9 to 11 days after administration)
Reported as:
Count of participants · Participants
Incidence of TEAEs Leading to Withdrawal From the Study
ParticipantsMild HIModerate HIHealthy Volunteers
Incidence of TEAEs Leading to Withdrawal From the Study000
SecondaryIncidence of Serious TEAEs (SAEs)

Number of participants with at least one Serious TEAE

Time frame:
From screening (28 to 2 days before administration) to End of Study (9 to 11 days after administration)
Reported as:
Count of participants · Participants
Incidence of Serious TEAEs (SAEs)
ParticipantsMild HIModerate HIHealthy Volunteers
Incidence of Serious TEAEs (SAEs)000
SecondaryIncidence of Clinically Significant Clinical Laboratory Parameters Abnormality

Number of participants with at least one clinically significant laboratory parameters abnormality. The following parameters were measured: Hematology: Hemoglobin, hematocrit, erythrocytes, platelets, leukocytes, and differential counts (basophils, eosinophils, lymphocytes, monocytes, neutrophils). Blood chemistry: Sodium, potassium, chloride, calcium, urea, creatinine, albumin, glucose, total proteins, triglycerides, total cholesterol, ALT, AST, GGT, CPK, alkaline phosphatase, total bilirubin. Coagulation: PT, INR, aPTT. Serology: HBsAg, anti-HBc, anti-HCV, anti-HIV-1/2, pregnancy test (hCG). Urinalysis: pH, protein, glucose, leukocytes, nitrites, ketones, blood. Other: Alcohol breath test; urine drug screen (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates).

Time frame:
From Baseline (28 to 2 days before administration) to End of Study (9 to 11 days after administration)
Reported as:
Count of participants · Participants
Incidence of Clinically Significant Clinical Laboratory Parameters Abnormality
ParticipantsMild HIModerate HIHealthy Volunteers
Incidence of Clinically Significant Clinical Laboratory Parameters Abnormality000
SecondaryIncidence of Clinically Significant Vital Signs Abnormality

Number of participants with at least one clinically significant vitals abnormality. The following clinical signs were measured: body temperature (C°), supine systolic blood pressure (mmHg), diastolic blood pressure (mmHg), pulse rate (beats/min), and respiratory rate (breath/min).

Time frame:
From Baseline (28 to 2 days before administration) to End of Study (9 to 11 days after administration)
Reported as:
Count of participants · Participants
Incidence of Clinically Significant Vital Signs Abnormality
ParticipantsMild HIModerate HIHealthy Volunteers
Incidence of Clinically Significant Vital Signs Abnormality000
SecondaryIncidence of Clinically Significant Electrocardiogram Abnormality

Number of participants with at least one clinically significant electrocardiogram abnormality. The following standard 12-lead ECG were recorded: heart rate (beats/min), PR interval (msec), QRS duration (msec), QRS axis (deg), QT interval (msec) and Fridericia and Bazett QTc interval (msec)

Time frame:
From Baseline (28 to 2 days before administration) to End of Study (9 to 11 days after administration)
Reported as:
Count of participants · Participants
Incidence of Clinically Significant Electrocardiogram Abnormality
ParticipantsMild HIModerate HIHealthy Volunteers
Incidence of Clinically Significant Electrocardiogram Abnormality000
SecondaryIncidence of Clinically Significant Physical Examination Abnormality

Number of participants with at least one clinically significant physical abnormality. A complete physical examination, including at a minimum assessments of the cardiovascular, respiratory, gastrointestinal, dermatological, neurological, and musculoskeletal systems, in addition to examinations of the head, eyes, ears, nose, throat, neck, and lymph nodes, as well as height and weight measurement.

Time frame:
From Baseline (28 to 2 days before administration) to End of Study (9 to 11 days after administration)
Reported as:
Count of participants · Participants
Incidence of Clinically Significant Physical Examination Abnormality
ParticipantsMild HIModerate HIHealthy Volunteers
Incidence of Clinically Significant Physical Examination Abnormality000

Adverse events

Collected over AEs were recorded from the time of informed consent through the EOS visit.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mild HI0/8 (0%)0/8 (0%)0/8 (0%)
Moderate HI0/8 (0%)0/8 (0%)2/8 (25%)
Healthy Volunteers0/8 (0%)0/8 (0%)1/8 (12.5%)
Most frequent other events
Most frequent other events
EventMild HIModerate HIHealthy Volunteers
DiarrhoeaGastrointestinal disorders0/81/80/8
Gastrooesophageal reflux diseaseGastrointestinal disorders0/81/80/8
Oral candidiasisInfections and infestations0/80/81/8

Baseline characteristics

Age, Continuous
Age, Continuous(year)Mild HIModerate HIHealthy VolunteersTotal
Mean54.1 ± 8.4461.9 ± 7.5138.6 ± 13.0951.5 ± 13.73
Sex: Female, Male
Sex: Female, Male(Participants)Mild HIModerate HIHealthy VolunteersTotal
Female33410
Male55414
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Mild HIModerate HIHealthy VolunteersTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0033
White88521
More than one race0000
Unknown or Not Reported0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Mild HIModerate HIHealthy VolunteersTotal
Hispanic or Latino0000
Not Hispanic or Latino88824
Unknown or Not Reported0000
Weight
Weight(kg)Mild HIModerate HIHealthy VolunteersTotal
Weight at screening77.89 ± 22.70178.98 ± 21.30379.04 ± 2.27478.63 ± 17.228
Weight at D-177.71 ± 22.50279.04 ± 21.14079.54 ± 1.90778.76 ± 17.074
BMI
BMI(kg/m2)Mild HIModerate HIHealthy VolunteersTotal
BMI at screening26.605 ± 6.263927.248 ± 6.272226.653 ± 2.106426.835 ± 5.0353
BMI at D-126.553 ± 6.230627.273 ± 6.200126.823 ± 2.128426.883 ± 4.9985
Child-Pugh score
Child-Pugh score(Scores on a scale (5 to 15))Mild HIModerate HIHealthy VolunteersTotal
Child-Pugh score at screening5.00 ± 0.0007.13 ± 0.354—6.06 ± 1.124
Child-Pugh score at D-15.00 ± 0.0007.38 ± 0.518—6.19 ± 1.276
08

Study locations

3 sites
  • MC COMAC Medical Ltd
    Sofia, 1606, Bulgaria
  • MC COMAC Medical Ltd
    Sofia, 1612, Bulgaria
  • Biotrial
    Rennes, 35042, France
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2025 to primary completion in Aug 2025, 2 months.

Results were first posted in Jun 2026, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2024
First posted
Dec 16, 2024
StartActual
May 29, 2025
Primary completionActual
Aug 14, 2025
CompletionActual
Aug 14, 2025
Results first posted
Jun 18, 2026
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06736223
Lead sponsor
Italfarmaco
Collaborators
Biotrial
Responsible party
Sponsor
First posted
Dec 16, 2024
Start date
May 29, 2025
Primary completion
Aug 14, 2025
Completion
Aug 14, 2025
Results posted
Jun 18, 2026
Last update
Jun 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Givinostat

Start the discussion